Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

被引：140

作者：

Kostense, S ^{[1
]}

Koudstaal, N

Sprangers, M

Weverling, GJ

Penders, G

Helmus, N

Vogels, R

Bakker, M

Berkhout, B

Havenga, M

Goudsmit, J

机构：

[1] Crucell Holland BV, Leiden, Netherlands

[2] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1012 WX Amsterdam, Netherlands

[3] Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1012 WX Amsterdam, Netherlands

[4] Univ Amsterdam, Acad Med Ctr, Ctr Poverty Related Communicable Dis, NL-1012 WX Amsterdam, Netherlands

来源：

AIDS | 2004年 / 18卷 / 08期

关键词：

D O I：

10.1097/00002030-200405210-00019

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The seroprevalence of adenovirus types 5 (Ad5) and 35 (Ad35) was investigated in patients at risk of AIDS. The seroprevalence of Ad5 was higher than Ad35 in HIV-infected patients from the Netherlands (60% versus 7%) and sub-Saharan Africa (90% versus 20%). The seroprevalence was similar among HIV-infected and uninfected individuals, and remained constant during progression to AIDS. Ad35 is less prone to neutralization than Ad5, encouraging the further development of Ad35 for vaccination against HIV.

引用

页码：1213 / 1216

页数：4

共 13 条

[1] Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen [J].

Bruña-Romera, O ;

González-Aseguinolaza, G ;

Hafalla, JCR ;

Tsuji, M ;

Nussenzweig, RS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) :11491-11496

[2] ADENOVIRUS ISOLATES FROM URINE OF PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME [J].

DEJONG, PJ ;

SPIGLAND, I ;

VALDERRAMA, G ;

HORWITZ, MS .

LANCET, 1983, 1 (8337) :1293-1296

[3]

EMINI E, 2002, 9 C RETR OPP INF SEA

[4] New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses [J].

Fallaux, FJ ;

Bout, A ;

Van der Velde, I ;

Van den Wollenberg, DJM ;

Hehir, KM ;

Keegan, J ;

Auger, C ;

Cramer, SJ ;

Van Ormondt, H ;

Van der Eb, AJ ;

Valerio, D ;

Hoeben, RC .

HUMAN GENE THERAPY, 1998, 9 (13) :1909-1917

[5] Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease [J].

Havenga, MJE ;

Lemckert, AAC ;

Ophorst, OJAE ;

van Meijer, M ;

Germeraad, WTV ;

Grimbergen, J ;

van den Doel, MA ;

Vogels, R ;

van Deutekom, J ;

Janson, AAM ;

de Bruijn, JD ;

Uytdehaag, F ;

Quax, PHA ;

Logtenberg, T ;

Mehtali, M ;

Bout, A .

JOURNAL OF VIROLOGY, 2002, 76 (09) :4612-4620

[6] Improved adenovirus vectors for infection of cardiovascular tissues [J].

Havenga, MJE ;

Lemckert, AAC ;

Grimbergen, JM ;

Vogels, R ;

Huisman, LGM ;

Valerio, D ;

Bout, A ;

Quax, PHA .

JOURNAL OF VIROLOGY, 2001, 75 (07) :3335-3342

[7] Development of adenovirus serotype 35 as a gene transfer vector [J].

Reddy, PS ;

Ganesh, S ;

Limbach, MP ;

Brann, T ;

Pinkstaff, A ;

Kaloss, M ;

Kaleko, M ;

Connelly, S .

VIROLOGY, 2003, 311 (02) :384-393

[8] Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector [J].

Sakurai, F ;

Mizuguchi, H ;

Hayakawa, T .

GENE THERAPY, 2003, 10 (12) :1041-1048

[9] Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity [J].

Shiver, JW ;

Fu, TM ;

Chen, L ;

Casimiro, DR ;

Davies, ME ;

Evans, RK ;

Zhang, ZQ ;

Simon, AJ ;

Trigona, WL ;

Dubey, SA ;

Huang, LY ;

Harris, VA ;

Long, RS ;

Liang, XP ;

Handt, L ;

Schleif, WA ;

Zhu, L ;

Freed, DC ;

Persaud, NV ;

Guan, L ;

Punt, KS ;

Tang, A ;

Chen, MC ;

Wilson, KA ;

Collins, KB ;

Heidecker, GJ ;

Fernandez, VR ;

Perry, HC ;

Joyce, JG ;

Grimm, KM ;

Cook, JC ;

Keller, PM ;

Kresock, DS ;

Mach, H ;

Troutman, RD ;

Isopi, LA ;

Williams, DM ;

Xu, Z ;

Bohannon, KE ;

Volkin, DB ;

Montefiori, DC ;

Miura, A ;

Krivulka, GR ;

Lifton, MA ;

Kuroda, MJ ;

Schmitz, JE ;

Letvin, NL ;

Caulfield, MJ ;

Bett, AJ ;

Youil, R .

NATURE, 2002, 415 (6869) :331-335

[10] Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: Addressing preexisting immunity to vaccine and gene therapy vectors [J].

Sprangers, MC ;

Lakhai, W ;

Koudstaal, W ;

Verhoeven, M ;

Koel, BF ;

Vogels, R ;

Goudsmit, J ;

Havenga, MJE ;

Kostense, S .

JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (11) :5046-5052

← 1 2 →